AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22825283 — intervention group
Group type: COMPARATOR
Intervention: Conventional weaning
Number of subjects: 20
Study 22825283 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV
Number of subjects: 20
Study 22825283 — intervention group
Group type: COMPARATOR
Intervention: NIV and Conventional weaning
Number of subjects: 20
Study 20376479 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression treatment (n = 8) - wore full leg compression stockings for 12 h after exercise
Number of subjects: 17
Study 20376479 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery (n = 9) - no intervention
Number of subjects: 17
Study 17990102 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin and paclitaxel
Number of subjects: 0
Study 17990102 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin and docetaxel
Number of subjects: 0
Study 15670888 — intervention group
Group type: EXPERIMENTAL
Intervention: dTpa formulation with 0.5 mg aluminium
Number of subjects: 647
Study 15670888 — intervention group
Group type: EXPERIMENTAL
Intervention: dTpa formulation with 0.3 mg aluminium
Number of subjects: 647
Study 15670888 — intervention group
Group type: EXPERIMENTAL
Intervention: dTpa formulation with 0.133 mg aluminium
Number of subjects: 647
Study 15670888 — intervention group
Group type: COMPARATOR
Intervention: dTpa formulations with varying aluminium content
Number of subjects: 647
Study 12572904 — intervention group
Group type: EXPERIMENTAL
Intervention: Consupren solution
Number of subjects: 11
Study 12572904 — intervention group
Group type: COMPARATOR
Intervention: Sandimmun Neoral solution
Number of subjects: 11
Study 9672517 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganglioside-supplemented formula
Number of subjects: 0
Study 9672517 — intervention group
Group type: COMPARATOR
Intervention: Control milk formula
Number of subjects: 0
Study 8024135 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane, nitrous oxide, and oxygen (12 patients)
Number of subjects: 19
Study 8024135 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane, air, and oxygen (7 patients)
Number of subjects: 19
Study 2691662 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified precision attachment design
Number of subjects: 10
Study 2691662 — intervention group
Group type: COMPARATOR
Intervention: Original prosthetic design
Number of subjects: 10
Study 4566958 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy (antrum innervated)
Number of subjects: 40
Study 4566958 — intervention group
Group type: COMPARATOR
Intervention: Selective vagotomy (antrum denervated)
Number of subjects: 40
Study 30363038 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Training Group (PTG)
Number of subjects: 21
Study 30363038 — intervention group
Group type: COMPARATOR
Intervention: Constant Training Group (CTG)
Number of subjects: 21
Study 31436447 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN)
Number of subjects: 801
Study 31436447 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Navigation with Contingency Management (PN + CM)
Number of subjects: 801
Study 28148500 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium with vitamin D (1000 mg elemental Ca with 400 IU vitamin D3/d)
Number of subjects: 5823
Study 28148500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5823
Study 25445634 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Number of subjects: 15
Study 25445634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 24100635 — intervention group
Group type: EXPERIMENTAL
Intervention: Household water filters
Number of subjects: 0
Study 21415458 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of dying (experimental group)
Number of subjects: 80
Study 21415458 — intervention group
Group type: COMPARATOR
Intervention: Dental anxiety (control group)
Number of subjects: 80
Study 19348536 — intervention group
Group type: EXPERIMENTAL
Intervention: Face Inversion
Number of subjects: 0
Study 19348536 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright Faces
Number of subjects: 0
Study 19348536 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverted Faces
Number of subjects: 0
Study 17898366 — intervention group
Group type: EXPERIMENTAL
Intervention: Clevidipine (0.4-8.0 microg x kg(‐1) x min(‐1))
Number of subjects: 152
Study 17898366 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20% lipid emulsion)
Number of subjects: 152
Study 15281537 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg wrapping with tight elastic bandages
Number of subjects: 60
Study 15281537 — intervention group
Group type: COMPARATOR
Intervention: Control group (no leg wrapping)
Number of subjects: 60
Study 15281537 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 11529331 — intervention group
Group type: EXPERIMENTAL
Intervention: Excretory-secretory (ES) products of Gnathostoma spinigerum infective larvae
Number of subjects: 0
Study 11529331 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic extract of Gnathostoma spinigerum infective larvae
Number of subjects: 0
Study 11529331 — intervention group
Group type: COMPARATOR
Intervention: Somatic antigen
Number of subjects: 0
Study 11529331 — intervention group
Group type: COMPARATOR
Intervention: Excretory-secretory (ES) antigen
Number of subjects: 0
Study 9790450 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte interferon-alpha (LE-IFN-alpha) administered at a dose of 3 MU three times a week for six months (group A)
Number of subjects: 24
Study 9790450 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte interferon-alpha (LE-IFN-alpha) administered at a dose of 3 MU three times a week for twelve months (group B)
Number of subjects: 24
Study 9790450 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte interferon-alpha (LE-IFN-alpha)
Number of subjects: 24
Study 8091119 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% triclosan in water-free propylene glycol (PG)
Number of subjects: 12
Study 8091119 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% triclosan with 1.5% SLS in PG
Number of subjects: 12
Study 8091119 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% triclosan in PG
Number of subjects: 12
Study 8091119 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075% triclosan in PG
Number of subjects: 12
Study 8091119 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% triclosan in diluted PG (1:8 in water) with 1.5% SLS
Number of subjects: 12
Study 8091119 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% triclosan in 0.5% sodium carbonate
Number of subjects: 12
Study 8091119 — intervention group
Group type: COMPARATOR
Intervention: water (negative control)
Number of subjects: 12
Study 8091119 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine acetate (CHX) (positive control)
Number of subjects: 12
Study 29462005 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation with gemcitabine (54 Gray external beam radiation) followed by surgery
Number of subjects: 110
Study 29462005 — intervention group
Group type: COMPARATOR
Intervention: Upfront surgery followed by chemoradiation
Number of subjects: 110
Study 29462005 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation
Number of subjects: 110
Study 29462005 — intervention group
Group type: COMPARATOR
Intervention: Upfront surgery
Number of subjects: 110
Study 27129425 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning vaccination (9-11 am)
Number of subjects: 276
Study 27129425 — intervention group
Group type: COMPARATOR
Intervention: Afternoon vaccination (3-5 pm)
Number of subjects: 276
Study 24090538 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-administered educational intervention about MRSA prevention (brochure and tools for nurses)
Number of subjects: 61
Study 24090538 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 61
Study 24090538 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-administered educational intervention about MRSA prevention
Number of subjects: 61
Study 22038174 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 and 40 mm femoral head
Number of subjects: 184
Study 22038174 — intervention group
Group type: COMPARATOR
Intervention: 32 mm femoral head
Number of subjects: 184
Study 20386323 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding started at 3 hours after PEG placement
Number of subjects: 40
Study 20386323 — intervention group
Group type: COMPARATOR
Intervention: Feeding started at 6 hours after PEG placement
Number of subjects: 40
Study 18435971 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplatzer
Number of subjects: 660
Study 18435971 — intervention group
Group type: EXPERIMENTAL
Intervention: Helex
Number of subjects: 660
Study 18435971 — intervention group
Group type: EXPERIMENTAL
Intervention: CardioSEAL-STARflex
Number of subjects: 660
Study 16169869 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily haemodialysis (DHD) for 8 weeks, six times/week, each session half the usual time
Number of subjects: 12
Study 16169869 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily haemodialysis (DHD)
Number of subjects: 12
Study 16169869 — intervention group
Group type: COMPARATOR
Intervention: Conventional haemodialysis (CHD)
Number of subjects: 12
Study 14690787 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 0
Study 14690787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10985320 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimonthly home collection of oral fluid (OF) specimens
Number of subjects: 241
Study 10985320 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimonthly home collection of dried blood spot (DBS) specimens
Number of subjects: 241
Study 10985320 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone results disclosure
Number of subjects: 241
Study 10985320 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimonthly testing
Number of subjects: 241
Study 8959286 — intervention group
Group type: EXPERIMENTAL
Intervention: High monoamine meal
Number of subjects: 10
Study 8959286 — intervention group
Group type: COMPARATOR
Intervention: Caffeine (one caffeinated cola per hour)
Number of subjects: 10
Study 8959286 — intervention group
Group type: COMPARATOR
Intervention: Nicotine (smoking one cigarette per hour)
Number of subjects: 10
Study 8959286 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam (2 mg IV push)
Number of subjects: 10
Study 8959286 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 10
Study 19186418 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermafil technique
Number of subjects: 80
Study 19186418 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentin plug
Number of subjects: 80
Study 19186418 — intervention group
Group type: COMPARATOR
Intervention: Obtura technique
Number of subjects: 80
Study 19186418 — intervention group
Group type: COMPARATOR
Intervention: Ultrafil technique
Number of subjects: 80
Study 19186418 — intervention group
Group type: COMPARATOR
Intervention: Touch 'n Heat technique
Number of subjects: 80
Study 19186418 — intervention group
Group type: COMPARATOR
Intervention: Control group (patent teeth)
Number of subjects: 80
Study 3902203 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin plus cisplatin
Number of subjects: 92
Study 3902203 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin alone
Number of subjects: 92
Study 30548121 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy formula (HF) 100 kcal/100 mL for 7 days
Number of subjects: 64
Study 30548121 — intervention group
Group type: COMPARATOR
Intervention: Standard formula 67 kcal/100 mL for 7 days
Number of subjects: 64
Study 30548121 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy formula (HF)
Number of subjects: 64
Study 30548121 — intervention group
Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 64
Study 29979610 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal shoulder tackle
Number of subjects: 13
Study 29979610 — intervention group
Group type: COMPARATOR
Intervention: Low tackle
Number of subjects: 13
Study 29979610 — intervention group
Group type: EXPERIMENTAL
Intervention: Opposite-leg tackle
Number of subjects: 13
Study 29979610 — intervention group
Group type: EXPERIMENTAL
Intervention: Low and opposite-leg tackle
Number of subjects: 13
Study 27538259 — intervention group
Group type: EXPERIMENTAL
Intervention: Live Attenuated Influenza Vaccine (LAIV)
Number of subjects: 1186
Study 27538259 — intervention group
Group type: COMPARATOR
Intervention: Inactivated Influenza Vaccine (IIV)
Number of subjects: 1186
Study 27538259 — intervention group
Group type: EXPERIMENTAL
Intervention: LAIV
Number of subjects: 1186
Study 27538259 — intervention group
Group type: COMPARATOR
Intervention: IIV
Number of subjects: 1186
Study 27538259 — intervention group
Group type: COMPARATOR
Intervention: LAIV vs IIV
Number of subjects: 1186
Study 24633761 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 300 mg daily for the first week, followed by 300 mg for the next 3 weeks, then discontinued with reassessment 8 weeks later.
Number of subjects: 15
Study 24633761 — intervention group
Group type: COMPARATOR
Intervention: Placebo during the first week of treatment.
Number of subjects: 15
Study 22899904 — intervention group
Group type: EXPERIMENTAL
Intervention: L. plantarum MF 1298 (10(10) CFU), once daily
Number of subjects: 16
Study 22899904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 20145228 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric banding
Number of subjects: 50
Study 20145228 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention
Number of subjects: 50
Study 18090697 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation therapy with ECT
Number of subjects: 201
Study 18090697 — intervention group
Group type: COMPARATOR
Intervention: Continuation therapy with medications
Number of subjects: 201
Study 15958319 — intervention group
Group type: EXPERIMENTAL
Intervention: L-ornithine-L-aspartate (40 ml in 250 ml 10% glucose and saline, once daily for 7 days)
Number of subjects: 85
Study 15958319 — intervention group
Group type: COMPARATOR
Intervention: Routine comprehensive therapy (control group)
Number of subjects: 85
Study 12107635 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Based Learning (PBL)
Number of subjects: 107
Study 12107635 — intervention group
Group type: COMPARATOR
Intervention: Lecture-Based Learning (LBL)
Number of subjects: 107
Study 9529179 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaster immobilization for 1 week
Number of subjects: 0
Study 9529179 — intervention group
Group type: COMPARATOR
Intervention: Plaster immobilization for 3 weeks
Number of subjects: 0
Study 7876629 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin
Number of subjects: 1875
Study 7876629 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 1875
Study 7876629 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 1875
Study 2192634 — intervention group
Group type: EXPERIMENTAL
Intervention: Efamol (evening primrose oil) at a dose of 6 capsules daily
Number of subjects: 200
Study 2192634 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equivalent dose of capsules)
Number of subjects: 200
Study 84895 — intervention group
Group type: EXPERIMENTAL
Intervention: Active immunisation with a clostridial toxoid prepared from type-C cultures
Number of subjects: 2500
Study 84895 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2500
Study 31377868 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiszasüly hot mud pack
Number of subjects: 60
Study 31377868 — intervention group
Group type: COMPARATOR
Intervention: Kolop hot mud pack
Number of subjects: 60
Study 30817721 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (50 min of moderate-intensity, supervised aerobic exercise, three times per week)
Number of subjects: 71
Study 30817721 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 71
Study 27709248 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-injection digital nerve block technique
Number of subjects: 50
Study 27709248 — intervention group
Group type: COMPARATOR
Intervention: Single-injection digital nerve block technique
Number of subjects: 50
Study 26184491 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestilan (6-15 g/day)
Number of subjects: 245
Study 26184491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study 23738530 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive-Behavioural Therapy (TF-CBT)
Number of subjects: 50
Study 23738530 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 50
Study 21436148 — intervention group
Group type: EXPERIMENTAL
Intervention: NoLAC (lactose-free milk protein-based formula)
Number of subjects: 128
Study 21436148 — intervention group
Group type: COMPARATOR
Intervention: LAC (standard commercial lactose-containing milk-based formula)
Number of subjects: 128
Study 21436148 — intervention group
Group type: EXPERIMENTAL
Intervention: NoLAC
Number of subjects: 128
Study 21436148 — intervention group
Group type: COMPARATOR
Intervention: LAC
Number of subjects: 128
Study 19863218 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary Lymph Edema (ALE)
Number of subjects: 204
Study 19863218 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm Pain
Number of subjects: 204
Study 19863218 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensation of Heaviness
Number of subjects: 204
Study 19863218 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-Related Quality of Life (HRQoL)
Number of subjects: 204
Study 19863218 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive Factors for HRQoL
Number of subjects: 204
Study 16924986 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond FL (3-step etch-and-rinse adhesive)
Number of subjects: 0
Study 16924986 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE (2-step self-etch adhesive)
Number of subjects: 0
Study 16924986 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond 1 (2-step etch-and-rinse adhesive)
Number of subjects: 0
Study 16924986 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt (1-step self-etch adhesive)
Number of subjects: 0
Study 16924986 — intervention group
Group type: EXPERIMENTAL
Intervention: FujiBond LC (2-step resin-modified glass-ionomer adhesive)
Number of subjects: 0
Study 16924986 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactmer (1-step resin-modified glass-ionomer adhesive)
Number of subjects: 0
Study 16924986 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-step etch-and-rinse adhesive (OptiBond FL)
Number of subjects: 0
Study 15247162 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (3 times/week for 12 weeks)
Number of subjects: 30
Study 15247162 — intervention group
Group type: COMPARATOR
Intervention: Electrical muscle stimulation (1 hour/day for 12 weeks)
Number of subjects: 30
Study 15247162 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation (1 hour/day for 12 weeks)
Number of subjects: 30
Study 11055468 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme (ACE) inhibitors
Number of subjects: 0
Study 11055468 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 0
Study 11055468 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy with beta-blockers and diuretics
Number of subjects: 0
Study 11055468 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis in diabetic patients
Number of subjects: 0
Study 9495994 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine 5 ml throat surface anesthesia (n = 40)
Number of subjects: 80
Study 9495994 — intervention group
Group type: COMPARATOR
Intervention: Control group without lidocaine (n = 40)
Number of subjects: 80
Study 8153921 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta 2 agonist plus corticosteroid (BA + CS) treatment
Number of subjects: 185
Study 8153921 — intervention group
Group type: COMPARATOR
Intervention: Bronchodilators only
Number of subjects: 185
Study 8153921 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator tests
Number of subjects: 185
Study 8153921 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator response at the start of the study
Number of subjects: 185
Study 2873740 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietetic, hygienic, and pharmacologic treatment including hypolipidemic agents (mainly probucol and clofibrate) and antihypertensive drugs (mainly diuretics and beta blockers)
Number of subjects: 1200
Study 2873740 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 1200
Study 2873740 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibrate plus probucol
Number of subjects: 1200
Study 2873740 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated subjects
Number of subjects: 1200
Study 2873740 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers or clofibrate
Number of subjects: 1200
Study 2873740 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol or diuretics
Number of subjects: 1200
Study 2873740 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (high risk and low risk)
Number of subjects: 1200
Study 30433830 — intervention group
Group type: EXPERIMENTAL
Intervention: Frail participants (defined as having three or more frailty parameters)
Number of subjects: 902
Study 30433830 — intervention group
Group type: EXPERIMENTAL
Intervention: Frail participants
Number of subjects: 902
Study 30433830 — intervention group
Group type: COMPARATOR
Intervention: Non-frail participants (defined as having two or fewer frailty parameters)
Number of subjects: 902
Study 28542391 — intervention group
Group type: EXPERIMENTAL
Intervention: Facility-based personalized maternal nutrition counseling
Number of subjects: 2253
Study 28542391 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 2253
Study 25864104 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombrabulin plus cisplatin (25 mg/m2 plus 75 mg/m2 every 3 weeks)
Number of subjects: 355
Study 25864104 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus cisplatin (placebo plus 75 mg/m2 every 3 weeks)
Number of subjects: 355
Study 25864104 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombrabulin plus cisplatin
Number of subjects: 355
Study 25864104 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus cisplatin
Number of subjects: 355